StreetInsider.com News Articles

H.C. Wainwright Upgrades Adlai Nortye Ltd. (ANL) to Buy

Fri, 13 Feb 2026 09:38:49 -0500

(Updated - February 13, 2026 9:38 AM EST)

H.C. Wainwright analyst Joseph Pantginis upgraded Adlai Nortye Ltd. (NASDAQ: ANL) from Neutral to Buy with a price target of $16.00.

The analyst commented: "We are upgrading to Buy and $16 price target from Neutral. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Our valuation is holistically split across Adlai's four clinical stage assets (each currently with 15% PoS): (1) AN9025 - 56% contribution; (2) AN8025 - 8% contribution; (3) AN4005 - 9% contribution; and (4) AN0025

H.C. Wainwright Upgrades Adlai Nortye Ltd. (ANL) to Buy

Fri, 13 Feb 2026 09:38:49 -0500

(Updated - February 13, 2026 9:38 AM EST)

H.C. Wainwright analyst Joseph Pantginis upgraded Adlai Nortye Ltd. (NASDAQ: ANL) from Neutral to Buy with a price target of $16.00.

Form 6-K Adlai Nortye Ltd. For: Feb 12

Thu, 12 Feb 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260212/25986472.html

Form 6-K Adlai Nortye Ltd. For: Feb 12

Thu, 12 Feb 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260212/25986472.html

Adlai Nortye doses first patient in phase 1 trial of cancer drug AN9025

Thu, 12 Feb 2026 04:00:09 -0500

Adlai Nortye Ltd. (NASDAQ: ANL) announced that the first patient received dosing of AN9025 in the United States in early February as part of its ongoing Phase 1 clinical trial. The company is testing the oral pan-RAS inhibitor in patients with advanced or metastatic solid tumors that harbor RAS mutations.

The Phase 1 study represents a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025. Adlai Nortye is conducting the trial in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. as a multi-regional clinical trial under a license agreement.

Under the licensing arrangement, Adlai Nortye retains

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Thu, 12 Feb 2026 04:00:00 -0500

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor.

The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Thu, 12 Feb 2026 04:00:00 -0500

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Thu, 12 Feb 2026 04:00:00 -0500

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Thu, 12 Feb 2026 04:00:00 -0500

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: Venrock Healthcare Capital Partners III, L.P.

Wed, 11 Feb 2026 17:12:00 -0500

si-local-file:///var/storage/secattach/20260211/25984635.html

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: Venrock Healthcare Capital Partners III, L.P.

Wed, 11 Feb 2026 17:12:00 -0500

si-local-file:///var/storage/secattach/20260211/25984635.html

Form SCHEDULE 13G/A Adlai Nortye Ltd. Filed by: Unique Mark Ventures Ltd

Mon, 09 Feb 2026 06:12:00 -0500

si-local-file:///var/storage/secattach/20260209/25964366.html

Form SCHEDULE 13G/A Adlai Nortye Ltd. Filed by: Unique Mark Ventures Ltd

Mon, 09 Feb 2026 06:12:00 -0500

si-local-file:///var/storage/secattach/20260209/25964366.html

Form 6-K Adlai Nortye Ltd. For: Feb 03

Tue, 03 Feb 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260203/25939426.html

Form 6-K Adlai Nortye Ltd. For: Feb 03

Tue, 03 Feb 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260203/25939426.html

Adlai Nortye raises $140 million in private placement financing

Tue, 03 Feb 2026 07:00:17 -0500

Adlai Nortye Ltd. (NASDAQ: ANL) announced it has entered into securities purchase agreements for a private investment in public equity financing expected to generate gross proceeds of approximately $140 million, before deducting placement agent fees and other expenses.

The clinical-stage biotechnology company is selling 64,615,386 Class A ordinary shares at $2.1667 per share, equivalent to 21,538,462 American Depositary Shares at $6.50 per ADS. Each ADS represents three Class A ordinary shares.

The private placement was co-led by Cormorant Asset Management and Columbia Threadneedle Investments. Other participants include both new and existing investors such as Balyasny Asset Management L.P., Point72, Squadron Capital Management

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Tue, 03 Feb 2026 07:00:00 -0500

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities purchase agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $140.0 million, before deducting placement agent fees and other expenses.

In the private placement, the Company is selling 64,615,386 Class A ordinary shares of the Company (equivalent of 21,538,462 American Depositary Shares, each representing 3

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Tue, 03 Feb 2026 07:00:00 -0500

In the private placement, the Company is selling 64,615,386 Class A ordinary shares of the Company (equivalent of 21,538,462 American Depositary Shares, each representing 3

Lucid Capital Markets Starts Adlai Nortye Ltd. (ANL) at Buy

Thu, 29 Jan 2026 06:05:49 -0500

Lucid Capital Markets analyst Christopher Liu initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $11.00.

The analyst comments "Adlai Nortye (ANL) is a clinical-stage biotechnology company focused on developing novel oncology therapies. We believe that the company’s pan-RAS inhibitor, AN9025, could be a significant potential value driver for shares as the asset becomes de-risked. Thus far, AN9025 has demonstrated a compelling preclinical

Lucid Capital Markets Starts Adlai Nortye Ltd. (ANL) at Buy

Thu, 29 Jan 2026 06:05:49 -0500

Lucid Capital Markets analyst Christopher Liu initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $11.00.

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: Unique Mark Ventures Ltd

Tue, 20 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260120/25863883.html

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: Unique Mark Ventures Ltd

Tue, 20 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260120/25863883.html

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: ANL Talent Ltd

Fri, 16 Jan 2026 07:04:00 -0500

si-local-file:///var/storage/secattach/20260116/25857779.html

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: ANL Talent Ltd

Fri, 16 Jan 2026 07:04:00 -0500

si-local-file:///var/storage/secattach/20260116/25857779.html

Form SCHEDULE 13G Adlai Nortye Ltd. Filed by: ANL Talent Ltd

Fri, 16 Jan 2026 07:04:00 -0500

si-local-file:///var/storage/secattach/20260116/25857780.html